Share This Article:

Can Purified Omega-3 Polyunsaturated Fatty Acids Supplementation Act Blood Pressure Levels in Untreated Normal-High Blood Pressure Subjects with Hypertriglyceridemia?

Abstract Full-Text HTML Download Download as PDF (Size:346KB) PP. 234-239
DOI: 10.4236/pp.2012.32031    4,803 Downloads   8,315 Views   Citations


Omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) from fish and fish oils appear to protect against coronary heart disease: their dietary intake is in fact inversely associated with cardiovascular disease morbidity/mortality in population studies. Recent evidence suggests that at least a part of this protective effect is mediated by a relatively small but significant decrease in blood pressure (BP) level. In fact, omega-3 PUFAs exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion, partly competing with omega-6 PUFAs for common metabolic enzymes and thereby decreasing the production of vasoconstrictor rather than vasodilator and anti-inflammatory eicosanoids. PUFAs also reduce angiotensin-converting enzyme (ACE) activity, angiotensin II formation. We retrospectively evaluated the long-term effect of a omega-3 PUFAs supplementation on the blood pressure level of 91 hypertriglyceridemic subjects with untreated normal-high blood pressure that were prescribed a 3 grams omega-3 PUFAs supplementation in order to improve their plasma lipid pattern. After 24 months of treatment, systolic blood pressure (SBP) meanly decreased by 2.6 +/- 2.5 mmHg (p = 0.001) and diastolic blood pressure (DBP) by 1.4 +/- 3.1 mmHg (p < 0.001), while basal heart rate decreased by 4.1 +/- 4.6 bpm (p < 0.001). Both SBP and DBP reduction were significantly related to the baseline SBP (p < 0.001) and DBP (p < 0.001), respectively. Diastolic blood pressure change was also inversely related to the patient’s age (p = 0.004). No significant difference was perceived in the metabolic syndrome subgroup. In our retrospective study, highly purified omega-3 PUFAs long-term supplementation is associated with a significant reduction in SBP, DBP, and basal heart rate in hypertriglyceridemic patients with normal-high blood pressure. The main determinants of the omega-3 PUFAs anti-hypertensive effect appear to be the basal blood pressure level and age. Future research will clarify if omega-3 PUFAs supplementation could improve the antihypertensive action of specific blood pressure lowering drug classes and of statins.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Leonarda De Rosa, "Can Purified Omega-3 Polyunsaturated Fatty Acids Supplementation Act Blood Pressure Levels in Untreated Normal-High Blood Pressure Subjects with Hypertriglyceridemia?," Pharmacology & Pharmacy, Vol. 3 No. 2, 2012, pp. 234-239. doi: 10.4236/pp.2012.32031.


[1] D. P. Begg, A. J. Sinclair, L. A. Stahl, M. L. Garg, M. Jois and R. S. Weisinger, “Dietary Protein Level Interacts with ω-3 Polyunsaterated Fatty Acid Deficiency to Induce Hypertension,” American Journal of Hypertension, Vol. 23, No. 2, 2010, pp. 125-128.
[2] U. N. Das, “Essential Fatty Acids and Their Metabolites Could Function as Endogenous HMG-CoA Reductase and ACE Enzyme Inhibitors, Anti-Arrhythmic, Anti-Hypertensive, Anti-Atherosclerotic, Anti-Inflammatory, Cytoprotective and Cardioprotective Molecules,” Lipids in Health and Disease, Vol. 7, 2008, p. 37.
[3] U. N. Das, “Interaction of Polyunsaturated Fatty Acids with Dietary Protein and Its Relationship to the Pathogenesis of Hypertension,” American Journal of Hypertension, Vol. 23, No. 2, 2010, pp. 111-112.
[4] D. Mozaffarian, R. Micha and S. Wallace, “Effects on Coronary Heart Disease of Increasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” PLoS Medicine, Vol. 7, 2010, Article ID: 1000252.
[5] J. M. Geleijnse, E. J. Giltay, D. E. Grobbee, A. R. Donders and F. Kok, “Blood Pressure Response to Fish Oil Supplementation: Metaregression Analysis of Randomized Trials,” Journal of Hypertension, Vol. 20, 2002, pp. 1493-1499. doi:10.1097/00004872-200208000-00010
[6] C. Borghi and A. F. G. Cicero, “Blood Pressure Modulating Properties of Omega-3 Polyunsaturated Fatty Acids(PUFA). Another PUFA Heart Protective Effect?” High Blood Pressure and Cardiovascular Prevention, Vol. 14, No. 2, 2007, pp. 1-7. doi:10.2165/00151642-200714020-00001
[7] D. G. Altman, “Practical Statistics for Medical Research,” Chapman and Hall, London, 1991.
[8] C. R. Mehta, N. R. Patel and A. A. Tsiatis, “Exact Significance Testing to Establish Treatment Equivalence with Ordered Categorical Data,” Biometrics, Vol. 40, No. 3, 1984, pp. 819-825. doi:10.2307/2530927
[9] A. H. Lichtenstein, L. J. Appel, M. Brands, et al., “Diet and Lifestyle Recommendations: Revision 2006. A Scientific Statement from the American Heart Association Nutrition Committee,” Circulation, Vol. 114, No. 1, 2006, pp. 82-96
[10] W. S. Harris, “Omega-3 Fatty Acids and Cardiovascular Disease a Case for Omega-3 Index as a New Risk Factor,” Pharmacological Research, Vol. 55, No. 3, 2007, pp. 217-223.
[11] H. O. Ventura, R. V. Milani, C. J. Lavie, et al., “Cycosporine-Induced Hypertension: Efficacy of Omega-3 Fatty Acids in Patients after Cardiac Transplantation,” Circulation, Vol. 88, 1993, pp. 11281-11285.
[12] F. Theis, J. M. Garry, P. Yaquoob, et al., “Association of n-3 Polyunsaturated Fatty Acids with Stability of Atherosclerotic Plaques: A Randomized Controlled Trial,” Lancet, Vol. 3161, 2003, pp. 477-485. doi:10.1016/S0140-6736(03)12468-3
[13] J. N. Din, S. A. Harding, C. J. Valerio, et al., “Dietary Intervention with Oil Rich Fish Reduces Platelet-Monocyte Aggregation in Man,” Atherosclerosis, Vol. 197, No. 1, 2008, pp. 290-296.
[14] D. Mozaffarian and E. B. Rimm, “Fish Intake, Contaminants, and Human Health: Evaluating the Risk and the Benefits,” JAMA, Vol. 296, No. 15, 2006, pp. 1885-1899. doi:10.1001/jama.296.15.1885
[15] T. Madsen, E. B. Schmidt and J. H. Christensen, “The Effect of n-3 Fatty Acids on C-Reactive Protein Levels in Patients with Chronic Renal Failure,” Journal of Renal Nutrition, Vol. 17, No. 4, 2007, pp. 258-263.
[16] G. Zhao, T. D. Etherton, K. R. Martin, P. J. Gilles, S. G. West and P. M. Kris-Etherton, “Dietary Alpha-Linolenic Acid Inhibits Proinflammatory Cytokine Production by Peripheral Blood Mononuclear Cells in Hypercholesterolemic Subjects,” American Journal of Clinical Nutrition, Vol. 85, No. 2, 2007, pp. 385-391.
[17] M. Itoh, T. Suganami, N. Satoh, et al., “Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 9, 2007, pp. 1918-1925. doi:10.1161/ATVBAHA.106.136853
[18] W. S. Harris, M. Gonzales, N. Laney, A. Sastre and A. M. Borkon, “Effects of Omega-3 Fatty Acids on Heart Rate in Cardiac Transplant Recipients,” American Journal of Cardiology, Vol. 98, No. 10, 2006, pp. 1393-1395. doi:10.1016/j.amjcard.2006.06.033
[19] J. H. Lee, J. H. O’Keefe, C. J. Lavie, R. Marchioli and W. S. Harris, “Omega-3 Fatty Acids for Cardioprotection,” Mayo Clinic Proceedings, Vol. 83, No. 3, 2008, pp. 324- 332. doi:10.4065/83.3.324
[20] C. M. Albert, H. Campos, M. J. Stampfer, et al., “Blood Levels of Long-Chain n-3 Fatty Acids and the Risk of Sudden Death,” New England Journal of Medicine, Vol. 346, No. 15, 2002, pp. 1113-1138. doi:10.1056/NEJMoa012918
[21] W. S. Harris, “The Omega-3 Index as a Risk Factor for Coronary Heart Disease,” American Journal of Clinical Nutrition, Vol. 87, No. 6, 2008, pp. 1997S-2002S.
[22] T. A. Mori, R. J. Woodman, “The Independent Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiovascular Risk Factors in Humans,” Current Opinion in Clinical Nutrition & Metabolic Car, Vol. 9, 2006, pp. 95-104. doi:10.1097/01.mco.0000214566.67439.58
[23] M. C. Morris, F. Sacks and B. Rosner, “Does Fish Oil Lower Blood Pressure? A Meta-Analysis of Controlled Trials,” Circulation, Vol. 88, No 2, 1993, pp. 523-533.
[24] R. S. Dokholyan, C. M. Albert, L. J. Appel, et al., “A Trial of Omega-3 Fatty Acids for Prevention of Hypertension,” American Journal of Cardiology, Vol. 93, No. 8, 2004, pp. 1041-1043. doi:10.1016/j.amjcard.2004.01.013
[25] M. L. De Rosa, et al., “Obesity, Weight Loss and Hypertension, Abstract of ASH, New York, 14-18 May 2005,” American Journal of Hypertension, Vol. 18, No. 5, 2005, p. 196A.
[26] M. L. De Rosa, et al., “Long-Term Risk of Hypertension and Weight Loss in Overweight Adults,” Journal of Clinical Hypertension, 2006.
[27] C. J. Liu, S. M. Conklin, S. B. Manuck, J. K. Yao and M. F. Muldoon, “Long-Chain Omega-3 Fatty Acids and Blood Pressure,” American Journal of Hypertension, Vol. 24, No. 10, 2011, pp. 1121-1126.
[28] T. A. Mori, “Omega-3 Fatty Acids and Hypertension in Humans,” Clinical and Experimental Pharmacology and Physiology, Vol. 33, No. 9, 2006, pp. 842-846. doi:10.1111/j.1440-1681.2006.04451.x

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.